Examining Braak's hypothesis by imaging Parkinson's disease

Movement Disorders

Volumn 25, Issue SUPPL. 1, 2010, Pages

  Brooks, David J ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Braak staging; Magnetic resonance imaging; Parkinson's disease; Positron emission tomography; SPECT; Transcranial sonography

Indexed keywords

NEUROTRANSMITTER; SYNUCLEIN; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

ARTICLE; BRAAK STAGING; BRAIN METABOLISM; BRAIN REGION; CHOLINERGIC SYSTEM; DOPAMINERGIC SYSTEM; ECHOGRAPHY; HIGH RISK POPULATION; HUMAN; HYPOTHESIS; LEWY BODY; MICROGLIA; NEUROIMAGING; NORADRENERGIC SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; SEROTONINERGIC SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRUCTURAL HOMOLOGY; SYMPATHETIC INNERVATION; TOPOGRAPHY; BRAIN; DIAGNOSTIC IMAGING; HEART; HOSPITALIZATION; INNERVATION; METABOLISM; METHODOLOGY; PARKINSONISM; PATHOLOGY; REVIEW; RISK FACTOR; SCINTISCANNING; VASCULARIZATION;

BRAIN; DIAGNOSTIC IMAGING; HEART; HUMANS; NEUROTRANSMITTER AGENTS; PARKINSONIAN DISORDERS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 77953468659     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22720     Document Type: Article

References (40)

1. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318: 121-134.
2. Ponsen MM, Stoffers D, Booij J, Van Eck-Smit BL, Wolters E, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004; 56: 173-181.
3. Stiasny-Kolster K, Doerr Y, Moller JC, et al. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 2005; 128 (Part 1): 126-137.
4. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006; 5: 235-245.
5. Banati RB, Myers R, Kreutzberg GW. PK ('peripheral benzodiazepine')-binding sites in the CNS indicate early and discrete brain lesions: microautoradiographic detection of [3H]PK11195 binding to activated microglia. J Neurocytol 1997; 26: 77-82.
6. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988; 38: 1285-1291.
7. Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol 2003; 106: 518-526.
8. Ouchi Y, Yoshikawa E, Sekine Y, et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 2005; 57: 168-175.
9. Gerhard A, Pavese N, Hotton GR, et al. Microglial activation in Parkinson's disease-its longitudinal course and correlation with clinical parameters: an [11C](R)-PK11195 PET study. Neurology 2004; 62 ( Suppl 5): A432.
10. Bohnen NI, Minoshima S, Giordani B, Frey KA, Kuhl DE. Motor correlates of occipital glucose hypometabolism in Parkinson's disease without dementia. Neurology 1999; 52: 541-546.
11. Hu MTM, Taylor-Robinson SD, Chaudhuri KR, et al. Cortical dysfunction in non-demented Parkinson's disease patients: a combined 31Phosphorus MRS and 18FDG PET study. Brain 2000; 123: 340-352.
12. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-319.
13. Edison P, Rowe CC, Rinne J, et al. Amyloid load in Lewy body dementia (LBD), Parkinson's disease dementia (PDD) and Parkinson's disease (PD) measured with C-11-PIB PET. Neurology 2007; 68: A98.
14. Hutchinson M, Raff U. Structural changes of the substantia nigra in Parkinson's disease as revealed by MR imaging. Am J Neuroradiol 2000; 21: 697-701.
15. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114: 2283-2301.
16. Brooks DJ, Frey KA, Marek KL, et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol 2003; 184: S68-S79.
17. Whone AL, Moore RY, Piccini P, Brooks DJ. Plasticity in the nigropallidal pathway in Parkinson's disease: an 18F-dopa PET study. Ann Neurol 2003; 53: 206-213.
18. Ito K, Nagano-Saito A, Kato T, et al. Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study. Brain 2002; 125 (Part 6): 1358-1365.
19. Rinne JO, Portin R, Ruottinen H, et al. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. Arch Neurol 2000; 57: 470-475.
20. Berg D, Siefker C, Ruprecht-Dorfler P, Becker G. Relationship of substantia nigra echogenicity and motor function in elderly subjects. Neurology 2001; 56: 13-17.
21. Sommer U, Hummel T, Cormann K, et al. Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 2004; 19: 1196-1202.
22. Comella CL, Nardine TM, Diederich NJ, Stebbins GT. Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson's disease. Neurology 1998; 51: 526-529.
23. Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996; 46: 388-393.
24. Eisensehr I, Linke R, Noachtar S, Schwarz J, Gildehaus FJ, Tatsch K. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder: comparison with Parkinson's disease and controls. Brain 2000; 123 (Part 6): 1155-1160.
25. Eisensehr I, Linke R, Tatsch K, et al. Increased muscle activity during rapid eye movement sleep correlates with decrease of striatal presynaptic dopamine transporters. IPT and IBZM SPECT imaging in subclinical and clinically manifest idiopathic REM sleep behavior disorder, Parkinson's disease, and controls. Sleep 2003; 26: 507-512.
26. Albin RL, Koeppe RA, Chervin RD, et al. Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology 2000; 55: 1410-1412.
27. Moore RY, Whone AL, Brooks DJ. Extrastriatal monoamine neuron function in Parkinson's disease: an 18F-dopa PET study. Neurobiol Dis 2008; 29: 381-390.
28. Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ. Tremor in Parkinson's disease and serotonergic dysfunction: an (11)C-WAY 100635 PET study. Neurology 2003; 60: 601-605.
29. Kim SE, Choi JY, Choe YS, Choi Y, Lee WY. Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT. J Nucl Med 2003; 44: 870-876.
30. Remy P, Doder M, Lees AJ, Turjanski N, Brooks DJ. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005; 128: 1314-1322.
31. Kuhl DE, Minoshima S, Fessler JA, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 1996; 40: 399-410.
32. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003; 60: 1745-1748.
33. Takatsu H, Nagashima K, Murase M, et al. Differentiating Parkinson disease from multiple-system atrophy by measuring cardiac iodine-123 metaiodobenzyl-guanidine accumulation. JAMA 2000; 284: 44-45.
34. Reinhardt MJ, Jungling FD, Krause TM, Braune S. Scintigraphic differentiation between two forms of primary dysautonomia early after onset of autonomic dysfunction: value of cardiac and pulmonary iodine-123 MIBG uptake. Eur J Nucl Med 2000; 27: 595-600.
35. Druschky A, Hilz MJ, Platsch G, et al. Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J Neurol Sci 2000; 175: 3-12.
36. Courbon F, Brefel-Courbon C, Thalamas C, et al. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease. Mov Disord 2003; 18: 890-897.
37. Goldstein DS, Holmes C, Cannon RO, III, Eisenhofer G, Kopin IJ. Sympathetic cardioneuropathy in dysautonomias. N Engl J Med 1997; 336: 696-702.
38. Goldstein DS, Holmes C, Li ST, Bruce S, Metman LV, Cannon RO, III. Cardiac sympathetic denervation in Parkinson disease. Ann Intern Med 2000; 133: 338-347.
39. Satoh A, Serita T, Seto M, et al. Loss of 123I-MIBG uptake by the heart in Parkinson's disease: assessment of cardiac sympathetic denervation and diagnostic value. J Nucl Med 1999; 40: 371-375.
40. Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry 2005; 76: 249-251.